CDB20:0002872 PLA2G2A — ITGB1

Experimentally validated in Human; Orthology-inferred in Mouse, Rat, Frog, Chicken, Macaque, Pig, Cow, Chimp, Horse, Marmoset, Sheep

Title

Journal:; Year Published:

Abstract

Pro-inflammatory secretory phospholipase A2 type IIA binds to integrins alphavbeta3 and alpha4beta1 and induces proliferation of monocytic cells in an integrin-dependent manner.

The Journal of biological chemistry, 2008; PubMed, Homo sapiens PLA2G2A — Homo sapiens ITGB1
ABSTRACT: Secretory phospholipase A2 group IIA (sPLA2-IIA) plays an important role in the pathogenesis of inflammatory diseases. Catalytic activity of this enzyme that generates arachidonic acid is a major target for development of anti-inflammatory agents. Independent of its catalytic activity, sPLA2-IIA induces pro-inflammatory signals in a receptor-mediated mechanism (e.g. through the M-type receptor). However, the M-type receptor is species-specific: sPLA2-IIA binds to the M-type receptor in rodents and rabbits, but not in human. Thus sPLA2-IIA receptors in human have not been established. Here we demonstrated that sPLA2-IIA bound to integrin alphavbeta3 at a high affinity (K(D)=2 x 10(-7) M). We identified amino acid residues in sPLA2-IIA (Arg-74 and Arg-100) that are critical for integrin binding using docking simulation and mutagenesis. The integrin-binding site did not include the catalytic center or the M-type receptor-binding site. sPLA2-IIA also bound to alpha4beta1. We showed that sPLA2-IIA competed with VCAM-1 for binding to alpha4beta1, and bound to a site close to those for VCAM-1 and CS-1 in the alpha4 subunit. Wild type and the catalytically inactive H47Q mutant of sPLA2-IIA induced cell proliferation and ERK1/2 activation in monocytic cells, but the integrin binding-defective R74E/R100E mutant did not. This indicates that integrin binding is required, but catalytic activity is not required, for sPLA2-IIA-induced proliferative signaling. These results suggest that integrins alphavbeta3 and alpha4beta1 may serve as receptors for sPLA2-IIA and mediate pro-inflammatory action of sPLA2-IIA, and that integrin-sPLA2-IIA interaction is a novel therapeutic target.

Proinflammatory secreted phospholipase A2 type IIA (sPLA-IIA) induces integrin activation through direct binding to a newly identified binding site (site 2) in integrins αvβ3, α4β1, and α5β1.

The Journal of biological chemistry, 2015; PubMed, Homo sapiens PLA2G2A — Homo sapiens ITGB1
ABSTRACT: Integrins are activated by signaling from inside the cell (inside-out signaling) through global conformational changes of integrins. We recently discovered that fractalkine activates integrins in the absence of CX3CR1 through the direct binding of fractalkine to a ligand-binding site in the integrin headpiece (site 2) that is distinct from the classical RGD-binding site (site 1). We propose that fractalkine binding to the newly identified site 2 induces activation of site 1 though conformational changes (in an allosteric mechanism). We reasoned that site 2-mediated activation of integrins is not limited to fractalkine. Human secreted phospholipase A2 type IIA (sPLA2-IIA), a proinflammatory protein, binds to integrins αvβ3 and α4β1 (site 1), and this interaction initiates a signaling pathway that leads to cell proliferation and inflammation. Human sPLA2-IIA does not bind to M-type receptor very well. Here we describe that sPLA2-IIA directly activated purified soluble integrin αvβ3 and transmembrane αvβ3 on the cell surface. This activation did not require catalytic activity or M-type receptor. Docking simulation predicted that sPLA2-IIA binds to site 2 in the closed-headpiece of αvβ3. A peptide from site 2 of integrin β1 specifically bound to sPLA2-IIA and suppressed sPLA2-IIA-induced integrin activation. This suggests that sPLA2-IIA activates αvβ3 through binding to site 2. sPLA2-IIA also activated integrins α4β1 and α5β1 in a site 2-mediated manner. We recently identified small compounds that bind to sPLA2-IIA and suppress integrin-sPLA2-IIA interaction (e.g. compound 21 (Cmpd21)). Cmpd21 effectively suppressed sPLA2-IIA-induced integrin activation. These results define a novel mechanism of proinflammatory action of sPLA2-IIA through integrin activation.
Basic Information on PLA2G2A
Ligand Name: phospholipase A2 group IIA
Other Symbols: PLA2B, PLA2L
Ligand Location: secreted based on perplexity, uniprot, cell membrane based on uniprot
HGNC Gene Symbol Report: PLA2G2A
GeneCards: PLA2G2A
HGNC Gene Group: Phospholipases
Basic Information on ITGB1
Receptor Name: integrin subunit beta 1
Other Symbols: FNRB, MSK12, MDF2, CD29, GPIIA
Receptor Location: cell membrane based on hpa, perplexity, uniprot
HGNC Gene Symbol Report: ITGB1
GeneCards: ITGB1
HGNC Gene Group: CD molecules, Integrins
Interactions with other Ligands for ITGB1
ADAM12 — ITGB1ADAM15 — ITGB1ADAM17 — ITGB1ADAM2 — ITGB1ADAM9 — ITGB1ANGPT1 — ITGB1CD14 — ITGB1CHAD — ITGB1COL11A1 — ITGB1COL18A1 — ITGB1COL1A1 — ITGB1COL1A2 — ITGB1COL2A1 — ITGB1COL3A1 — ITGB1COL4A1 — ITGB1COL4A3 — ITGB1COL4A4 — ITGB1COL4A5 — ITGB1COL4A6 — ITGB1COL5A1 — ITGB1CXCL12 — ITGB1F13A1 — ITGB1FBLN1 — ITGB1FBN1 — ITGB1FGA — ITGB1VEGFD — ITGB1FN1 — ITGB1HSPG2 — ITGB1ICAM4 — ITGB1LAMA1 — ITGB1LAMA2 — ITGB1LAMA4 — ITGB1LAMA5 — ITGB1LAMB1 — ITGB1LAMB3 — ITGB1LAMC1 — ITGB1LAMC2 — ITGB1LGALS3BP — ITGB1MATN1 — ITGB1MDK — ITGB1NID1 — ITGB1NPNT — ITGB1PLG — ITGB1RELN — ITGB1SEMA7A — ITGB1SPP1 — ITGB1TGM2 — ITGB1THBS1 — ITGB1THBS2 — ITGB1TIMP2 — ITGB1TNC — ITGB1VCAM1 — ITGB1VCAN — ITGB1VEGFA — ITGB1VEGFC — ITGB1VTN — ITGB1ANGPTL2 — ITGB1CCN4 — ITGB1CLEC11A — ITGB1LGALS1 — ITGB1SPON2 — ITGB1ADAM28 — ITGB1AGGF1 — ITGB1AGRN — ITGB1ANGPT2 — ITGB1ANGPTL4 — ITGB1CCN2 — ITGB1CCN3 — ITGB1CD40LG — ITGB1CDH1 — ITGB1COL10A1 — ITGB1COL11A2 — ITGB1COL13A1 — ITGB1COL4A2 — ITGB1COL8A1 — ITGB1COL8A2 — ITGB1CSPG4 — ITGB1CX3CL1 — ITGB1ICAM5 — ITGB1IL1B — ITGB1JAM2 — ITGB1L1CAM — ITGB1LAMA3 — ITGB1LAMB2 — ITGB1LGALS3 — ITGB1LGALS8 — ITGB1MFGE8 — ITGB1MIA — ITGB1NTN4 — ITGB1PLAUR — ITGB1SVEP1 — ITGB1TGFB1 — ITGB1TGFB3 — ITGB1THBS4 — ITGB1THY1 — ITGB1TIMP1 — ITGB1VWF — ITGB1